TITLE

Item response analysis of the Positive and Negative Syndrome Scale

AUTHOR(S)
Santor, Darcy A.; Ascher-Svanum, Haya; Lindenmayer, Jean-Pierre; Obenchain, Robert L.
PUB. DATE
January 2007
SOURCE
BMC Psychiatry;2007, Vol. 7, p66
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Statistical models based on item response theory were used to examine (a) the performance of individual Positive and Negative Syndrome Scale (PANSS) items and their options, (b) the effectiveness of various subscales to discriminate among individual differences in symptom severity, and (c) the appropriateness of cutoff scores recently recommended by Andreasen and her colleagues (2005) to establish symptom remission. Methods: Option characteristic curves were estimated using a nonparametric item response model to examine the probability of endorsing each of 7 options within each of 30 PANSS items as a function of standardized, overall symptom severity. Our data were baseline PANSS scores from 9205 patients with schizophrenia or schizoaffective disorder who were enrolled between 1995 and 2003 in either a large, naturalistic, observational study or else in 1 of 12 randomized, double-blind, clinical trials comparing olanzapine to other antipsychotic drugs. Results: Our analyses show that the majority of items forming the Positive and Negative subscales of the PANSS perform very well. We also identified key areas for improvement or revision in items and options within the General Psychopathology subscale. The Positive and Negative subscale scores are not only more discriminating of individual differences in symptom severity than the General Psychopathology subscale score, but are also more efficient on average than the 30-item total score. Of the 8 items recently recommended to establish symptom remission, 1 performed markedly different from the 7 others and should either be deleted or rescored requiring that patients achieve a lower score of 2 (rather than 3) to signal remission. Conclusion: This first item response analysis of the PANSS supports its sound psychometric properties; most PANSS items were either very good or good at assessing overall severity of illness. These analyses did identify some items which might be further improved for measuring individual severity differences or for defining remission thresholds. Findings also suggest that the Positive and Negative subscales are more sensitive to change than the PANSS total score and, thus, may constitute a "mini PANSS" that may be more reliable, require shorter administration and training time, and possibly reduce sample sizes needed for future research.
ACCESSION #
34910954

 

Related Articles

  • Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study. Ganguli, Rohan; Brar, Jaspreet S.; Mahmoud, Ramy; Berry, Sally A.; Pandina, Gahan J. // BMC Medicine;2008, Vol. 6, Special section p1 

    Background: In clinical practice, physicians often need to change the antipsychotic medications they give to patients because of an inadequate response or the presence of unacceptable or unsafe side effects. However, there is a lack of consensus in the field as to the optimal switching strategy...

  • An antipsychotic's side effects derail a patient's symptom management.  // Clinical Advisor;Aug2010, Vol. 13 Issue 8, p45 

    The article presents a case study of a 30 year-old man with history of schizoaffective disorder. It states that he suffers from auditory hallucinations, paranoid delusions, and periods of insomnia and underwent six months of treatment using stabilized olanzapine. It also mentions that the...

  • Evaluation of Quality of Life for Patients with Schizophrenic and Schizoaffective Disorders Related to the Use of Antipsychotic Therapy. Golubovic, Boris; Misic-Pavkov, Gordana; Gajic, Zoran; Ivanovic-Kovacevic, Svetlana // Medicinski Arhiv;2010, Vol. 64 Issue 1, p37 

    The purpose of the study was to understand the impact of using antipsychotics in the treatment of schizophrenic and schizoaffective disorders related to the quality of life and overall social functioning of schizophrenic patients. In addition to this, the study monitored and compared the...

  • Neuroleptic malignant syndrome in a patient with newly diagnosed schizoaffective disorder. Inal, Mehmet Turan // Internet Journal of Anesthesiology;2007, Vol. 13 Issue 3, p3 

    Neuroleptic malignant syndrome is a rare but fatal complication when using neuroleptic drugs. We report a case involving a 47-year-old woman with newly diagnosed schizoaffective disorder who presented with neuroleptic malignant syndrome after an increase in her neuroleptic dose.

  • Safety of Paliperidone Extended-Release in Patients with Schizophrenia or Schizoaffective Disorder and Hepatic Disease. Amatniek, Joan; Canuso, Carla M.; Deutsch, Stephen I.; Henderson, David C.; Mao, Lian; Mikesell, Chris; Rodriguez, Stephen; Sheehan, John; Alphs, Larry // Clinical Schizophrenia & Related Psychoses;Spring2014, Vol. 8 Issue 1, p8 

    Abstract Background/Purpose: Patients with schizophrenia often suffer from comorbid hepatic disease. This multicenter, open-label, single-arm, crossover study evaluated the safety and efficacy of paliperidone extended-release (ER) in patients with schizophrenia or schizoaffective disorder and...

  • The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Goldberg, Terry E.; Greenberg, Richard D.; Griffin, Suzanne J.; Gold, James M.; Kleinman, Joel E.; Pickar, David; Schulz, S. Charles; Weinberger, Daniel R.; Goldberg, T E; Greenberg, R D; Griffin, S J; Gold, J M; Kleinman, J E; Pickar, D; Schulz, S C; Weinberger, D R // British Journal of Psychiatry;Jan93, Vol. 162, p43 

    Psychiatric symptoms and cognition were assessed in 13 patients with schizophrenia, one patient with schizoaffective disorder, and one patient with psychosis not otherwise specified while they received a conventional neuroleptic and again after an average of 15 months on clozapine. Despite...

  • Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population. Kumar Rout, Jayanta; Dasgupta, Anindya; Singh, Om Prakash; Banerjee, Ushasi; Das, Brahmarshi // Journal of Neurosciences in Rural Practice;Sep-Dec2012, Vol. 3 Issue 3, p277 

    Context: For any given body mass, Asian Indians have higher central obesity than Europeans. A periodic measurement of body mass index (BMI) and waist hip ratio (WHR) is practically more feasible than other parameters of metabolic syndrome by repeated blood collection. However, few studies are...

  • Greater weight increases with olanzapine than with risperidone.  // Reactions Weekly;7/2/2005, Issue 1058, p4 

    Presents the results of a study that compared the effects of olanzapine and risperidone use in patients with schizophrenia or schizoaffective disorders. Drug which caused a significant increase in body weight and visceral adiposity after 24 weeks; Patients who experienced impaired secretory...

  • The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Bottlender, Ronald; Sato, Tetsuya; J�ger, Markus; Groll, Constanze; Strau�, Anton; M�ller, Hans-J�rgen // European Archives of Psychiatry & Clinical Neuroscience;2002, Vol. 252 Issue 5, p226 

    Objective: The aim of the study was to investigate the association between the duration of untreated psychosis, premorbid functioning and outcome from first inpatient treatment in schizophrenic or schizoaffective patients. Method: The data of 196 first-hospitalized patients with a schizophrenic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics